With a pair of deals worth more than US$1.7 B, AstraZeneca has taken steps to strengthen and expand its immuno-oncology portfolio, partnering with Innate Pharma for the co-development and commercialisation of the Phase II anti-NKG2A antibody IPH2201 and out-licensing its immune checkpoint inhibitor MEDI4736 (durvalumab) to Celgene for development in haematological malignancies. AstraZeneca also plans to test the two assets in combination in solid tumours, adding to the company’s broad programme of combination trials in immuno-oncology.